SCHEMBL13221268

SCHEMBL13221268

Cc1cc(Nc2nc(Sc3cccc(C(=O)O)c3)cc3nccn23)n[nH]1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CCNA1 P78396 1/20 0.39
▸ AURKA O14965 11/20 0.38
▸ AURKB Q96GD4 6/20 0.38
▸ ITK Q08881 1/20 0.38
▸ GSK3B P49841 4/20 0.37
▸ SRC P12931 3/20 0.37
▸ ENPP2 Q13822 2/20 0.37
▸ EGFR P00533 1/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ ATM Q13315 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NTRK1 P04629 1/20 0.35
▸ SYK P43405 1/20 0.35
▸ AURKC Q9UQB9 1/20 0.35
▸ JAK2 O60674 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13221272 0.92 MAP4K2 (0.40) CCNA2CDK2CCNA1AURKAAURKB
SCHEMBL13221266 0.91 PTK2 (0.39) CCNA2CDK2CCNA1AURKAAURKB
SCHEMBL13221270 0.90 AURKA (0.43) AURKAAURKBITKGSK3BSRC
SCHEMBL13221275 0.87 PRKAG1 (0.36) AURKAAURKBITKGSK3BSRC
SCHEMBL13221262 0.85 AURKA (0.39) AURKAAURKBITKGSK3BSRC
SCHEMBL13221278 0.84 CDK7 (0.36) AURKAAURKBGSK3BSRCAURKC
SCHEMBL13221269 0.83 AURKA (0.42) AURKAAURKBGSK3BSRCAURKC
SCHEMBL13221279 0.82 RET (0.36) AURKAAURKBGSK3BSRCAURKC
SCHEMBL13221276 0.81 RET (0.43) AURKAAURKBAURKC
SCHEMBL13221307 0.81 AURKB (0.40) AURKAAURKBITKGSK3BSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-8288536-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-16 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-20100216765-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-26 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed
US-7713973-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216765-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 CCNA2 703/4885CDK2 74/4885CCNA1 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback